Premium
Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R
Author(s) -
Benton Christopher B.,
Khan Maliha,
Sallman David,
Nazha Aziz,
Nogueras González Graciela M.,
Piao Jin,
Ning Jing,
Aung Fleur,
Al Ali Najla,
Jabbour Elias,
Kadia Tapan M.,
Borthakur Gautam,
Ravandi Farhad,
Pierce Sherry,
Steensma David,
DeZern Amy,
Roboz Gail,
Sekeres Mikkael,
Andreeff Michael,
Kantarjian Hagop,
Komrokji Rami S.,
GarciaManero Guillermo
Publication year - 2018
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25234
Subject(s) - international prognostic scoring system , medicine , proportional hazards model , hazard ratio , cohort , myelodysplastic syndromes , risk stratification , confidence interval , bone marrow
The International Prognostic Scoring System‐Revised (IPSS‐R) is one standard for myelodysplastic syndrome (MDS) risk stratification. It divides patients into five categories including an intermediate subset (IPSS‐R int‐risk). Outcomes and clinical interventions for patients with IPSS‐R int‐risk are not well defined. We performed an analysis of outcomes of this group of patients. Out of 3167 patients, a total of 298 were identified with IPSS‐R int‐risk MDS and retrospectively analyzed to assess characteristics affecting outcomes. Cox proportional hazard models for overall survival (OS) were performed to identify statistically significant clinical factors that influence survival. Age of 66 years or greater, peripheral blood blasts of 2% or more, and history of red blood cell (RBC) transfusion were significantly associated with inferior survival. Based on these features, MDS patients with IPSS‐R int‐risk were classified into two prognostic risk groups for analysis, an int‐favorable group and an int‐adverse group, and had significantly divergent outcomes. Sequential prognostication was validated using two independent datasets comprising over 700 IPSS‐R int‐risk patients. The difference in median survival between int‐favorable and int‐adverse patients was 3.7 years in the test cohort, and 1.8 and 2.0 years in the two validation cohorts. These results confirm significantly variable outcomes of patients with IPSS‐R int‐risk and need for different prognostic systems.